Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose Prolia PK variability study in healthy postmenopausal women
ACTRN12621000728831Phase 4Not yet recruiting
- Sponsor
- New Zealand Clinical Research
- Start
- Jul 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of denosumab in osteoporosis, sponsored by New Zealand Clinical Research. Primary endpoint: Pharmacokinetic parameters of Prolia. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ACTRN12621000728831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621000728831.